Suppr超能文献

Difelikefalin 治疗血液透析患者瘙痒症的疗效和安全性:一项荟萃分析和系统评价。

Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.

出版信息

Clin Nephrol. 2024 Apr;101(4):155-163. doi: 10.5414/CN111169.

Abstract

BACKGROUND

The incidence of pruritus associated with hemodialysis (HD) patients can be as high as 70%, and ~ 40% of patients suffer from moderate to severe systemic pruritus. Difelikefalin (CR845), a peripheral restrictor κ-opioid receptor agonist, activates opioid receptors on peripheral neurons and immune cells to relieve pruritus in patients. However, the clinical effect of difelikefalin on HD-related pruritus is unclear. Therefore, the purpose of this meta-analysis and systematic review was to investigate the safety and efficacy of difelikefalin in the treatment of HD-associated pruritus.

OBJECTIVE

This study explored the efficacy and safety of difelikefalin in the treatment of pruritus in HD patients by systematic review and meta-analysis.

MATERIALS AND METHODS

Randomized controlled trials on difelikefalin in the treatment of pruritus in HD patients were retrieved from PubMed, Embase, Cochrane Library, and Web of Science electronic databases. The retrieval deadline was January 1, 2023. Stata 15.0 software was used for data analysis of the included studies.

RESULTS

A total of 4 randomized controlled trials were included, totaling 1,268 patients (736 patients in the experimental group and 532 patients in the control group). Results of the meta-analysis showed that, compared with the control group, difelikefalin could significantly improve the Worst Itch Numeric Rating Scale score (improvement > 3; risk ratio (RR) = 1.28, 95% confidence interval (CI) (1.07, 1.53)), decrease the 5-D itch score (standardized mean difference = -0.43, 95% CI (-0.55, -0.30)), and significantly improve adverse events (RR = 1.33, 95% CI (1.13, 1.56)).

CONCLUSION

Although difelikefalin can improve itching symptoms in HD patients, it can also increase adverse reactions based on the current literature. Therefore, more studies are needed to further explore the safety and efficacy of difelikefalin treatment.

摘要

背景

接受血液透析(HD)治疗的患者瘙痒发生率可高达 70%,约 40%的患者患有中重度全身性瘙痒。地氟可来(CR845)是一种外周限制κ阿片受体激动剂,可激活外周神经元和免疫细胞上的阿片受体,缓解患者的瘙痒症状。然而,地氟可来治疗与 HD 相关的瘙痒的临床疗效尚不清楚。因此,本项荟萃分析和系统评价旨在研究地氟可来治疗与 HD 相关瘙痒的安全性和有效性。

目的

本研究通过系统评价和荟萃分析探讨地氟可来治疗 HD 患者瘙痒的疗效和安全性。

材料和方法

从 PubMed、Embase、Cochrane 图书馆和 Web of Science 电子数据库中检索关于地氟可来治疗 HD 患者瘙痒的随机对照试验。检索截止日期为 2023 年 1 月 1 日。采用 Stata 15.0 软件对纳入研究进行数据分析。

结果

共纳入 4 项随机对照试验,共计 1268 例患者(实验组 736 例,对照组 532 例)。荟萃分析结果显示,与对照组相比,地氟可来能显著改善最差瘙痒数字评定量表评分(改善>3;风险比(RR)=1.28,95%置信区间(CI)(1.07,1.53)),降低 5-D 瘙痒评分(标准化均数差=-0.43,95%CI(-0.55,-0.30)),且显著增加不良反应(RR=1.33,95%CI(1.13,1.56))。

结论

虽然地氟可来能改善 HD 患者的瘙痒症状,但基于目前的文献,也会增加不良反应。因此,需要更多的研究来进一步探讨地氟可来治疗的安全性和疗效。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验